CorMedix (NASDAQ: CRMD) — Company Overview, News & Financial Data
CorMedix is a biopharmaceutical company focused on therapeutic products to prevent infections in dialysis patients.
CorMedix
CorMedix (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is primarily known for its lead product, DefenCath, a novel catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in patients on hemodialysis through central venous catheters. CorMedix aims to address the significant unmet medical needs in reducing infections in the hospital and dialysis settings, making strides in the fight against antibiotic resistance. With a commitment to innovation and patient care, CorMedix is dedicated to improving outcomes for patients and healthcare systems worldwide.
Snapshot
Operations
Products and/or services of CorMedix
- DefenCath/Neutrolin, a catheter lock solution preventing bloodstream infections in hemodialysis patients.
- Development of taurolidine-based therapies for antimicrobial resistance.
- Pipeline exploring taurolidine in different formulations for various medical applications.
- Research on novel solutions to combat biofilm-associated infections.
- Collaborations with healthcare entities to extend product accessibility.
- Engagement in awareness campaigns about catheter-related bloodstream infections and their prevention.
CorMedix executive team
- Joseph TodiscoCEO & Chairman of the Board of Directors
- Elizabeth Masson-HurlburtExecutive VP and Chief Operating & Commercial Officer
- Kaufman Beth ZelnickEVP, Chief Legal and Compliance Officer & Corporate Secretary
- Susan BlumEVP & Chief Financial Officer
- Beth SteinbrennerSVP & Chief Human Resource Officer
- Matthew T. DavidEVP & Chief Business Officer
- Donna UcciSenior VP & Head of Global Quality
- Tushar MukherjeeSenior VP & Head of Technical Operations
- Peter SullivanSenior Vice President of Market Access
- Jared L. CrandonExecutive Director of Clinical Portfolio Management